Cell-Penetrating Bispecific Antibodies for Targeting Oncogenic Transcription Factors in Advanced Prostate Cancer
Abstract
The goal of these studies is to develop and validate cell-penetrating bi-specific antibodies as an agent that can selectively inhibit the function of intracellular proteins. We have developed 3E10-AR441 bi-specific antibody to inhibit the function both ligand-dependent and independent forms of the androgen receptor (AR), key drivers of prostate carcinogenesis. Key accomplishments in this reporting period are the production of a prototype 3E10-AR441 bi-specific antibody, and demonstration of target engagement under denaturing and non-denaturing conditions, as well as in intact cell systems. The antibody inhibited the growth of prostate cancer cells. We will continue to characterize the biochemical lesions produced by this antibody, while developing higher affinity analogs with improved production characteristics.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2013
- Accession Number
- ADA597878
Entities
People
- Michael Lilly
Organizations
- Medical University of South Carolina